Humana's antitrust claims against Epic survive dismissal, but this is an early-stage procedural ruling with no immediate financial impact. Monitor for summary judgment motions and potential settlement developments as discovery progresses. The MDL remains active, and any eventual recovery would likely be years away.
Price Chart
Executive Summary
In the Generic Pharmaceuticals MDL, Judge Rufe ruled on Epic Pharma's motions to dismiss antitrust claims regarding Ursodiol pricing. Humana's complaint was among eight that survived dismissal, as the court found sufficient allegations that Epic conspired with Lannett and Actavis to raise Ursodiol prices over 1000%. Three other complaints (HCSC, Molina, CVS) were dismissed against Epic for insufficient pleading. This is an interlocutory ruling—the case continues against Epic for Humana, with no damages awarded or financial exposure quantified.
Court Ruling Details
Key Facts
- Humana Inc. is a plaintiff in the multidistrict antitrust litigation against generic drug manufacturers over price-fixing of Ursodiol.
- The court denied Epic Pharma's motion to dismiss Humana's complaint, finding it sufficiently alleged Epic conspired to raise Ursodiol prices.
- The ruling is interlocutory—no damages have been awarded; the case proceeds to discovery.
- Three other complaints (HCSC, Molina, CVS) were dismissed against Epic for failure to state a claim.
- No financial exposure or damages amount is stated in the opinion.
Financial Impact
No damages or financial exposure quantified in the ruling.
Risk Factors
- No damages have been awarded; the case is in early discovery stage.
- Epic may succeed on summary judgment or at trial.
- Any potential recovery for Humana is uncertain and likely years away.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-1as9hv5f-HUM |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 1, 2026 4w ago | 8-K | $394.45 $381.57 | ▼ −3.26% | ▼ −3.58% | $382.43 (−3.05%) |
Aug 17, 2026 6w ago | Institutional Cluster | $382.00 $384.72 | ▲ +0.71% | ▲ +2.02% | $382.43 (+0.11%) |
Aug 13, 2026 7w ago | Court Ruling | $384.97 $409.80 | ▲ +6.45% | ▲ +8.20% | $382.43 (−0.66%) |
Jul 29, 2026 9w ago | 8-K | $365.41 $391.06 | ▲ +7.02% | ▲ +2.00% | $382.43 (+4.66%) |
Jun 1, 2026 17w ago | 8-K | $328.31 $388.90 | ▲ +18.46% | ▲ +20.77% | $382.43 (+16.49%) |
Apr 10, 2026 24w ago | 8-K | $197.53 $274.15 | ▲ +38.79% | ▲ +31.06% | $382.43 (+93.61%) |
Mar 6, 2026 30w ago | DEFA14A | $179.09 $182.71 | ▲ +2.02% | ▲ +4.07% | $382.43 (+113.55%) |
Mar 2, 2026 30w ago | Court Ruling | $187.00 $166.00 | ▼ −11.23% | ▼ −3.29% | $382.43 (+104.51%) |
Mar 2, 2026 30w ago | Court Ruling | $187.00 $166.00 | ▼ −11.23% | ▼ −3.29% | $382.43 (+104.51%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access